Ad26.RSV.preF-RSV preF protein vaccine immunogenic in seniors
Feb 16, 2023
Vaccination results in lower RSV-mediated lower respiratory tract disease meeting one of three definitions.
COVID-19 mRNA vaccines safe during pregnancy
Feb 13, 2024
In a large study, there were lower odds of neonatal mortality associated with vaccination.
COVID-19 vaccination bests natural immunity for cutting death, hospitalizations
Dec 28, 2022
Natural immunity, however, was tied to a lower incidence of new infection.
COVID-19 vaccine protection lasts at least six months after second dose
Feb 07, 2023
Vaccine effectiveness against death was lower for patients aged 80 years and older.
Intention to receive COVID-19 vaccine has grown faster among Black adults
Feb 02, 2022
A persistent lower vaccination rate in Black adults might be explained by other factors besides hesitancy.
Vaccination cuts risk for myocardial infarction, stroke after COVID-19
Jul 29, 2022
The findings show a lower hospitalization risk 31 to 120 days after COVID-19 infection.
mRNA COVID-19 efficacy lower for immunocompromised adults
Nov 04, 2021
Vaccine effectiveness of two doses of mRNA vaccine lower against COVID-19-associated hospitalization, with variation by condition. mRNA vaccines approved to fight COVID-19 in the U.S. include Pfizer-BioNTech...
CDC: Vaccinated more likely to die during omicron wave if they got J&J shot
Mar 25, 2022
However, breakthrough infections among J&J vaccine recipients were similar or lower compared with the other vaccines.
Risk for breakthrough SARS-CoV-2 infection lower with mRNA-1273
Feb 02, 2022
The risk for breakthrough infection and of 60-day hospitalization was significantly lower for mRNA-1273 (Moderna) versus BNT162b2 (Pfizer-BioNTech) vaccination.
FDA approves first RSV vaccine
May 03, 2023
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.